Clinical Trial Update: Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A [Phase 3]

View source ↗

Summary

Phase 3 trial comparing high-titer versus low-titer anti-influenza immune plasma for severe Influenza A; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Infection

Drugs mentioned

• immune plasma (high-titer)
• immune plasma (low-titer)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Influenza A Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-06-14